Key Highlights for Investors

• Return to Profitability: Anika Therapeutics, Inc. (Nasdaq: ANIK) reported a net income of \$3.3 million for the second quarter ended June 30, 2026, marking a notable turnaround from a net loss of \$4.0 million in the same quarter last year.
• Improved Earnings Per Share (EPS): The diluted earnings per share for Q2 2026 was \$0.24, compared to a loss per share of \$0.28 in Q2 2025. For the six-month period, the company reported a net loss per diluted share of \$0.13, significantly improved from a loss of \$0.62 per share in the prior year.
• Shareholder Equity Remains Strong: As of June 30, 2026, total stockholders’ equity stood at \$137.3 million, down slightly from \$143.5 million at year-end 2025, reflecting modest capital management and share repurchases.
• No Preferred Shares Outstanding: No preferred stock was issued or outstanding during the period, indicating common stockholders are the primary equity holders.
• Active Capital Management: The company continued to repurchase common shares, with 775,000 shares repurchased in Q1 2026, and modest retirement of shares for minimum tax withholdings, reflecting continued efforts to manage capital structure and potentially enhance shareholder value.
• Regulatory Compliance: The company remains compliant with all SEC reporting obligations, and continues to be listed on the Nasdaq Global Select Market under the ticker ANIK.

Detailed Financial Analysis

Condensed Consolidated Income Statement

For the three months ended June 30, 2026, Anika Therapeutics posted net income of \$3.3 million, or \$0.24 per diluted share. This positive result follows a year of losses, reflecting improvements in operational efficiency, cost controls, or recovery in sales. For the six months ended June 30, 2026, the company reported a net loss of \$1.7 million, or \$0.13 per diluted share. This is a significant improvement over the first half of 2025, which saw a net loss of \$8.9 million, or \$0.62 per diluted share.

Comprehensive income for Q2 reached \$3.3 million, compared to a comprehensive loss of \$2.6 million for the same period in 2025, signaling a recovery in both core operations and other components of equity.

Balance Sheet Position

• Total Assets: \$183.5 million as of June 30, 2026, down from \$190.3 million at December 31, 2025, reflecting continued investment in operations and share repurchases.
• Stockholders’ Equity: \$137.3 million, representing approximately 75% of the company’s total assets, a strong indicator of financial health and low leverage.
• Common Shares Outstanding: 13,383,000 shares as of June 30, 2026, down from 13,889,000 at the end of 2025, due to share repurchases and tax-related retirements.

Shareholder-Focused Updates & Potential Price-Sensitive Items

• Return to Profitability: The swing to profitability in Q2 2026 is a significant and potentially price-sensitive event. After a challenging 2025, the company’s renewed earnings power may support a re-rating by investors and analysts.
• Active Share Repurchase: The company’s ongoing share repurchase activity could signal management’s confidence in the intrinsic value of the business and can provide support to the share price.
• Cost Discipline and Margin Improvement: While not all details are disclosed, the improvement in net results suggests better cost control and/or sales recovery, which investors will want to monitor in future disclosures.
• No Indication of Dilution Risk: With no preferred shares outstanding and the reduction in shares via buybacks, dilution risk for common shareholders is low.
• Regulatory Stability: The company remains in full compliance with SEC filing requirements, an important reassurance for institutional investors.

Conclusion – What Investors Should Watch

The Q2 2026 results from Anika Therapeutics, Inc. represent a notable turnaround, with a return to quarterly profitability and ongoing shareholder-friendly actions such as buybacks. Investors should closely monitor subsequent quarters for sustained profitability, further capital returns, and any strategic updates that could affect future valuation. The company’s prudent balance sheet and capital management provide a solid foundation for future growth or resilience against market volatility.